Selective laser trabeculoplasty (SLT) has been indicated as a safe and efficient treatment for primary open-angle glaucoma; however, recent studies have also shown positive results with the use of SLT in some clinical conditions related to primary angle-closure glaucoma (PACG). Despite the potential benefits of SLT in selected cases of PACG, the mechanisms underlying the modifications in the trabecular meshwork tissue of patients with PACG are poorly understood. This narrative review approached both the current, limited knowledge about the histological changes observed in different forms of PACG and the clinical results of SLT treatment for PACG. Favourable outcomes of SLT in patients with PACG, specifically in areas of non-occluded angle, need further substantiation through large controlled clinical trials. A deeper understanding of the biomolecular changes of those areas is essential to improve both laser technical details and the clinical efficacy of SLT therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ceo.12938 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty.
Am J Ophthalmol
January 2025
Piedmont Eye Center, Lynchburg, Virginia.
Purpose: To evaluate the intraocular pressure (IOP)-lowering effect and safety of up to two bimatoprost implant administrations versus selective laser trabeculoplasty (SLT).
Design: Phase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687).
Participants: Patients (n=183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy.
New treatments for glaucoma.
Curr Opin Ophthalmol
January 2025
New York Eye Surgery Center, New York City, New York, USA.
Purpose Of Review: This review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.
Recent Findings: New FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant.
Association of Matrix Metalloproteinases Polymorphisms with Glaucoma Risk, Glaucoma Phenotype, and Response to Treatment with Selective Laser Trabeculoplasty or Latanoprost.
Int J Mol Sci
December 2024
Department of Ophthalmology, University Medical Centre Ljubljana, Grablovičeva 46, 1000 Ljubljana, Slovenia.
In open-angle glaucoma, the increase in intraocular pressure (IOP) is caused by an increased resistance to aqueous humour outflow in the trabecular meshwork. Since genetic variability of matrix metalloproteinase (MMP) genes may influence extracellular matrix remodelling, we investigated their association with glaucoma risk and/or response to treatment. The retrospective part of the study included patients with primary open-angle glaucoma and ocular hypertension (OHT); in the prospective part of the study, newly diagnosed patients with POAG or OHT were randomised to receive either latanoprost or selective laser trabeculoplasty (SLT) as the initial treatment.
View Article and Find Full Text PDFEffect of first-line and second-line selective laser trabeculoplasty on corneal hysteresis in patients with normal tension glaucoma: a multicenter study.
Graefes Arch Clin Exp Ophthalmol
January 2025
Department of Ophthalmology, Shimane University Faculty of Medicine, Izumo, Japan.
One-year outcomes of selective laser trabeculoplasty for open-angle glaucoma in Indian eyes.
Indian J Ophthalmol
December 2024
Department of Ophthalmology, Sri Sathya Sai Institute of Higher Medical Sciences, Prasanthigram, Andhra Pradesh, India.
Purpose: To assess the effectiveness of selective laser trabeculoplasty (SLT) in Indian eyes with open-angle glaucoma (OAG).
Settings And Design: Single-center, prospective, interventional study.
Methods: Patients undergoing SLT from January 2014 to June 2018 for OAG were included in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!